bioMerieux targets breast cancer theranostics with Ipsen
This article was originally published in Clinica
Executive Summary
Marcy l'Etoile-based diagnostics company bioMerieux is to collaborate with fellow French pharmaceutical firm Ipsen on diagnostic-and-therapy solution for breast cancer patients. Under the agreement, bioMerieux will develop a test to determine which patients are best suited to benefit from a new breast cancer drug, BN83495, that Paris-based Ipsen is currently investigating. The test, based on bioMerieux's NucliSENS EasyQ molecular diagnostics platform, will be used in the clinical development of the Ipsen drug and for diagnostic purposes, with the potential for future commercialisation. According to WHO figures, breast cancer is the most prevalent form of cancer worldwide with 1.1 million new cases diagnosed each year. The disease is responsible for over 500,000 deaths each year.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.